ClinicalTrials.gg
Enrolling by invitationNCT06096220Updated Apr 13, 2026

Usage of 5-fluorouracil and Carnoy's Solution in Surgical Treatment of Odontogenic Keratocysts

A Phase 4 interventional study of Enucleation and incisional biopsy in Odontogenic Keratocyst, sponsored by University of Belgrade. Enrolling by invitation at 1 site in Serbia. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University of Belgrade · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2023, registered Sep 2023).
Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare surgical treatment outcomes of odontogenic keratocysts (OKC) treated with enucleation and local application of Carnoy's solution or 5% 5-fluorouracil. The main questions it aims to answer are:

  1. What is the recurrence rate of OKC treated with enucleation and local application of 5% 5-fluorouracil cream in the period of three and five years after the treatment
  2. What is the recurrence rate of OKC treated with enucleation and local application of Carnoy's solution in the period of three and five years after the treatment
  3. Is there a difference in the recurrence rate between these two groups
  4. What is the frequency of sensitivity disorders in the innervation zone of inferior alveolar and infraorbital nerves in both groups

Participants will be assigned to one of two groups after Histopathological verification (HP verification).They will be treated with enucleation and local application of Carnoy's solution or 5% 5-fluorouracil depending on group. After surgical treatment they will be monitored in accordance to standard treatment protocols for patients with OKC.

02

Conditions studied

  • Odontogenic Keratocyst
03

In context

Lead sponsor

University of Belgrade is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • verified OKC of the upper or lower jaw;
  • Indicated surgical treatment of OKC

Exclusion criteria

Exclusion Criteria:

  • to 5-fluorouracil and Carnoy's solution;
  • Pathological fracture of the jaw in OKC region.
  • Nevoid basal cell carcinoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Enucleation of OKC followed by local application of 5% 5-fluorouracil cream. Drug will be applied on the gauze left in the enucleation defect for 24 hours, after which the gauze will be removed.

    Procedure: Enucleation · Diagnostic Test: incisional biopsy · Drug: Application of 5-fluorouracil

  • Active comparator
    Control group

    Enucleation of OKC followed by local application Carnoy solution. Carnoy solution will be applied into the cystic cavity for 5 minutes and bone defect will be treated by Carnoy solution for 3 minutes immediately after the enucleation.

    Procedure: Enucleation · Diagnostic Test: incisional biopsy · Drug: Application of Carnoy solution

Interventions

  • ProcedureEnucleation

    Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.

  • Diagnostic testincisional biopsy

    Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC

  • DrugApplication of 5-fluorouracil

    5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours

  • DrugApplication of Carnoy solution

    Carnoy solution will be applied during the enucleation as described previously

06

What researchers measure

Primary outcomes

  1. Recurrence rate

    Number of participants with histologically verified OKC in site of previously treated OKC

    Time frame: 5 years

Secondary outcomes

  1. Sensitivity disorders

    dysesthesia and hypoesthesia in the surgical site

    Time frame: Immediately after the surgery up to one month

07

Study locations

1 site
  • School of Dental Medicine
    Belgrade, 11000, Serbia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06096220
Lead sponsor
University of Belgrade
Responsible party
Miroslav Andric (Professor of Oral Surgery and Implantology, University of Belgrade) — Principal investigator
First posted
Oct 23, 2023
Start date
Jun 10, 2023
Primary completion
Jun 10, 2025
Completion
Jun 10, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Miroslav Andric
study chair · University of Belgrade, School of Dental Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion